GlassScriptPhysician profile
Erin Marcia Simms
NPI 1366098402
$5,869.15
in general payments reported to CMS, 2019-2025
33 companies · $754 in 2025
The $754 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,361 · 2022: $1,303 · 2023: $1,230 · 2024: $1,222 · 2025: $754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,195 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,194.68 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,626.46 | 2021-2025 | Biktarvy, Descovy |
| Viiv Healthcare Company | $1,311.18 | 2021-2025 | Dovato, Cabenuva, Apretude |
| Merck Sharp & Dohme LLC | $379.23 | 2021-2025 | Pifeltro, Delstrigo, Capvaxive |
| Novo Nordisk INC | $373.70 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $220.36 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Janssen Products, LP | $214.43 | 2021-2023 | Symtuza |
| Abbvie INC. | $191.65 | 2021-2024 | |
| Janssen Biotech, INC. | $146.14 | 2021-2023 | Symtuza |
| Amgen INC. | $131.08 | 2023-2025 | Repatha, Otezla, Repatha |
| Theratechnologies INC. | $126.38 | 2021-2024 | Trogarzo, Egrifta |
| Antares Pharma, INC. | $117.69 | 2021-2024 | Xyosted, Tlando, Nocdurna |
| Otsuka America Pharmaceutical, INC. | $97.92 | 2024-2025 | Rexulti |
| Napo Pharmaceuticals INC | $94.26 | 2022-2024 | Mytesi |
| Pfizer INC. | $91.30 | 2024-2025 | |
| Glaxosmithkline, LLC. | $80.84 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $78.53 | 2023-2024 | Serostim |
| Astrazeneca Pharmaceuticals LP | $75.68 | 2021-2025 | Airsupra |
| Almatica Pharma LLC | $72.67 | 2021-2024 | Loreev Xr |
| Janssen Pharmaceuticals, INC | $65.74 | 2021-2024 | Spravato |
| Esperion Therapeutics, INC. | $44.16 | 2023-2024 | Nexletol |
| Idorsia Pharmaceuticals US INC | $43.39 | 2023-2024 | Quviviq |
| Lundbeck LLC | $42.82 | 2022-2023 | Brintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.06 | 2021 | |
| Eisai INC. | $36.05 | 2021 | |
| Janssen Scientific Affairs, LLC | $34.96 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.89 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.60 | 2024 | Caplyta |
| Kowa Pharmaceuticals America, INC. | $15.92 | 2022 | |
| Neos Therapeutics, LP | $14.87 | 2024 | Adzenys Xr-Odt |
| Supernus Pharmaceuticals, INC. | $14.65 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.64 | 2025 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $12.49 | 2022 | |
| Arbor Pharmaceuticals, INC. | $11.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Simms listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.